| AR | Androgen receptor |
| ATR | Ataxia telangiectasia and rad3-related kinase |
| CTCs | Circulating tumor cells |
| ctDNA | Circulating tumor DNA |
| DSB | Double strand break |
| EAU | European Association of Urology |
| ESMO | European Society of Medical Oncology |
| FANC | Fanconi Anemia |
| FDA | Food and Drug Administration |
| HR | Hazard ratio |
| HRD | Homologous recombination deficiency |
| HRR | Homologous recombination repair |
| mCRPC | Metastatic castration-resistant prostate cancer |
| mCSPC | Metastatic castration-sensitive prostate cancer |
| MMR | Mismatch repair |
| NCCN | National Comprehensive Cancer Network |
| NGS | Next-generation screening |
| NHT | Next-generation hormonal therapy |
| ORR | Objective radiological response |
| OS | Overall survival |
| PARP | Poly-ADP-ribose polymerase |
| PARPi | PARP inhibitor |
| PCa | Prostate cancer |
| PFS | Progression-free survival |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| rPFS | Radiological progression-free survival |
| SSB | Single strand break |